Clinical trial NCT00604903: Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal
Official title: Remon CHF Medical Device Clinical Investigation PAPIRUS II: Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure
Lead sponsor: Boston Scientific Corporation
Sponsor class: INDUSTRY
First posted: 2008-01-30
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The purpose of this study is to evaluate and document appropriate clinical safety and performance of the Remon CHF Implantable Pressure Sensor including the corresponding delivery system, the Remon CHF Home Unit, the Remon CHF Clinic System devices and associated application software. It is a small clinical trial to determine the feasibility of the device. The primary outcome measure relates to feasibility and not to health outcomes.

Detailed description: This study was a prospective feasibility, non-randomised, singlearm, multi-centre, interventional clinical investigation performed at 4 international sites. Patients were implanted with the Remon CHF Implantable Pressure Sensor utilizing the corresponding delivering system. Measurements were taken with the Remon CHF Home Unit and the Remon CHF Clinic System. Follow-up visits took place at one, three and six months after implant.

Per protocol, a minimum of 30 patients was required to demonstrate safety of the device.

The study was conducted in accordance with ISO 14155:2003 (parts I and II), the Declaration of Helsinki and all applicable local and national regulations in the countries of submission.

Eligibility criteria: Inclusion Criteria:

* Patients who exhibit signs and symptoms of NYHA Class III or IV heart failure.
* Patients who are able to visit the clinic frequently during the 6 months following implantation.
* Patients who are willing and able to perform all follow-up procedures.

Exclusion Criteria:

1. Patients under the age of 18
2. Pregnant women or women that plan to get pregnant during the study.
3. Patients with, tricuspid or pulmonic stenosis, pulmonary stents, right sided mechanical heart valves
4. Contraindication to antiplatelet therapy (aspirin and clopidogrel)
5. Patients suffering from active infection (on antibiotic therapy)
6. Known intracardiac mass (right atrial or right ventricular)
7. Patients who have been implanted with a VAD
8. Patients who are candidates for listing for heart transplantation if it is deemed that they have a possibility of receiving a heart within the next 6 months
9. Patients that have lead implanted at the heart right side of the heart within the last 6 months
10. Patients with any terminal illness, or with a life expectancy of less than 6 months
11. Patients that are unable to lie flat for the duration of the procedure
12. Patients that are unable to operate the home unit (due to physical or mental constrain)
13. Patients after pneumonectomy
14. Patients treated with oral anticoagulants INR \> 1.5 prior to catheterization
15. Patients with severe chronic renal failure (creatinine \> 2.5 mg/dl)
16. Patients suffered from acute myocardial infarction within the three months prior the study
17. Patients that underwent open heart surgery within 4 weeks prior the study.

Primary outcomes:
measure: Serious adverse events related to implantation or the device
timeFrame: 6
Secondary outcomes:
measure: Device accuracy
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
affiliation: CardioVascular Center Frankfurt, Seckbacher
name: Horst Sievert, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hoppe UC, Vanderheyden M, Sievert H, Brandt MC, Tobar R, Wijns W, Rozenman Y. Chronic monitoring of pulmonary artery pressure in patients with severe heart failure: multicentre experience of the monitoring Pulmonary Artery Pressure by Implantable device Responding to Ultrasonic Signal (PAPIRUS) II study. Heart. 2009 Jul;95(13):1091-7. doi: 10.1136/hrt.2008.153486. Epub 2009 Feb 5.